News
The notion that we should require placebo trials even when there's already a safe, effective vaccine goes against decades of ...
The EMA now advises against using the drug for people aged over 65 after 17 serious adverse effects were recorded in this age ...
The FDA and CDC are recommending a pause on the use of Ixchiq (chikungunya vaccine, live) in patients 60 years and older during an ongoing safety investigation.
The approval applies to anyone aged 18 and older who has a risk of being exposed to the virus. But the FDA and the Centers ...
The CDC recommends the vaccine pause while it investigates “serious adverse events,” including neurologic and cardiac events.
US health officials are telling travelers aged 60 and older to avoid a chikungunya vaccine while they investigate possible side effects.
The U.S. government advised American travelers age 60 and older not get a chikungunya vaccine as it investigates possible side effects. The Centers for Disease Control and Prevention and the Food and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results